Compass Pathways has announced six‑month results from its second phase 3 trial of COMP360, its synthetic formulation of ...
Summer's here and we're turning up the heat with another sizzling edition of PharmaTimes. Hot topics include how our industry ...
Option offers once‑daily semaglutide tablets for adults living with obesity A first‑of‑its‑kind daily GLP‑1 weight‑loss pill has launched in the UK, expanding treatment options for adults living with ...
Novartis has secured European Commission approval for Itvisma for the treatment of children aged two years and older, as well ...
AlzeCure Pharma has signed an out‑licensing and collaboration agreement with Danish biotech QuantumCell ApS, granting global ...
Applications have opened for the ninth cohort of KQ Labs, the national accelerator for data‑driven health start‑ups delivered ...
R1 Therapeutics has formed a scientific advisory board comprising seven internationally recognised nephrology experts as the ...
Agomab Therapeutics has announced the design of its phase 2b NOV‑ERA study of ontunisertib in fibrostenosing Crohn’s disease, ...
Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 June in ...
Racura Oncology has treated the first patient in its phase 1 HARNESS‑1 clinical trial of RC220 for EGFR‑mutant non‑small cell ...
First immunotherapy approved for LACC in England offers new treatment option for women MSD has welcomed the National Institute for Health and Care Excellence’s recommendation of pembrolizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results